Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
OBJECTIVES: Pretreatment prostate specific antigen (PSA) is a strong predictor of prostate cancer outcome after radiotherapy and is a key parameter in pretreatment risk assessment. Because PSA is secreted from both benign and malignant tissue, a prior transurethral resection of prostate (TURP) may lower pretreatment PSA levels out of proportion to the extent of cancer. The purpose of this study was to determine whether a history of TURP is associated with increased biochemical failure (BF) after definitive radiotherapy for prostate cancer. METHODS: From April 1989 to October 2001, 1135 men with low to intermediate risk T1c-2NX/0M0 (2002 AJCC) prostate cancer with a pretreatment PSA less than 20 ng/mL received three-dimensional conformal radiotherapy (median dose, 76 Gy) without androgen deprivation. The median pretreatment PSA was 7.4 ng/mL (range, 0.4 to 19.9). There were 126 men with a prior history of TURP. The Cox proportional hazards model was used for univariate and multivariate
Related Questions
- Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
- Does A TURP (Transurethral Resection of Prostate) Affect the Outcomes of a RRP(Radical Retropubic Prostatectomy)?
- What are the side effects of transurethral resection of the prostate (TURP)?
